Fig. 2From: A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC studyRepresentation of treatment schedule and study inclusion for patients with HER2 positive breast cancerBack to article page